1.. Introduction {#S1}
================

The Centers for Disease Control and Prevention (CDC), National Birth Defects Study has published data suggesting that "environmental" exposures including maternal thyroid diseases, maternal nicotine exposure, and use of selective serotonin reuptake inhibitors (SSRIs) by pregnant mothers may exacerbate incidence and or severity of craniofacial anomalies including craniosynostosis ([@R7]; [@R12]; [@R29]). Thyrotoxicosis, (often transient) maternal hyperthyroidism occurs in 1 in every 500 pregnancies and has been associated with sagittal and coronal craniosynostosis in the fetus or infant ([@R16]). Despite the link between adverse birth outcomes of pre- and perinatal nicotine exposure, research suggests 11% of women in the United States continue to smoke or use alternative nicotine products through the third trimester of pregnancy ([@R31]; [@R62]; [@R65]; [@R11]; [@R24]). Approximately 25% of depressed women continue SSRI therapy after becoming pregnant (accounting for up to 1--8% of pregnancies) ([@R25]; [@R45]; [@R51]). Together these environmental exposures create an at-risk population particularly susceptible to birth defects including craniosynostosis and its associated comorbidities.

Craniosynostosis is a birth defect defined as the premature fusion of the suture(s) of the skull occurring in 1:1800--2500 births. This premature fusion of cranial sutures occurs before cessation of brain growth. When craniosynostosis is part of a syndrome, it is usually associated with facial, limb, ear, or heart malformations ([@R35]), but most often occurs in isolation (nonsyndromic) ([@R5]). There is significant morbidity for craniosynostosis resulting from secondary effects of fusion including altered intracranial pressure and volume ([@R8]), dilation of the subarachnoid spaces ([@R13]), optic nerve compression, papilledema, blindness ([@R48]), cognitive disabilities, and mental retardation ([@R48]; [@R3]). These severe abnormalities pose extensive, costly, and recurrent clinical/surgical management problems imposing significant emotional and financial burdens upon patients and families ([@R14]; [@R26]). In the overwhelming majority of craniosynostosis cases, the specific etiology is unknown as it can result from intrinsic genetic (*i.e.* mutations in *FGFR, TWIST, TGFβ)*, extrinsic environmental factors as indicated above, or gene-environment interactions ([@R61]; [@R22]).

A proposed mechanism of craniosynostosis is the disruption of the balance of proliferation and differentiation of the osteogenic precursors in the perisutural area leading to bone growth within cranial sutures ([@R37]; [@R1]; [@R27]; [@R54]; [@R53]; [@R56]; [@R59]; [@R68]). The balance of cell types within the perisutural space is tightly controlled to maintain the fibrous tissue (capsular layer) between bone fronts (cambium layer) that is vital for proper brain and skull growth and development. Recently, undifferentiated cells identified as Gli1^+^ CD44^+^ Sca1^+^ have been identified in craniofacial bones and sutures ([@R71]). Further, ablation of these undifferentiated cells has been correlated with fusion of the sutures (craniosynostosis). Since the population of undifferentiated cells in this area has been found to decrease with age, and suture fusion may occur naturally after growth is complete, it is possible that maintenance of this population is necessary for suture patency ([@R71]; [@R46]; [@R67]).

Here we sought to determine if environmental exposure to pharmacological agents known to increase the risk of craniosynostosis including those used to treat maternal thyroid disorder (levothyroxine), mimic maternal nicotine use, and maternal use of SSRI (citalopram) can specifically affect the stem cells resident to the newly defined suture stem cell niche. Our hypothesis, based on the CDC data, was that these pharmacological exposures would deplete stem cells resident to the calvarial sutures, precipitating premature suture fusion and abnormal craniofacial form.

2.. Materials and methods {#S2}
=========================

2.1.. Pharmacological exposure animal model {#S3}
-------------------------------------------

Adult wild type, C57BL6 (Mus *musculus,* Jackson Laboratories, Bar Harbor, ME) male and female mice were utilized to produce *in utero* exposed litters. Control litters were produced from breeding pairs that were not exposed to any pharmacological agents (*n*=49 pups). Levothyroxine (Synthroid, 1 μg/day) was added to the drinking water of pregnant dams from E13-E20, a critical period for craniofacial development (*n*=19 pups) ([@R58]; [@R40]; [@R10]; [@R64]; [@R9]; [@R18]; [@R41]; [@R42]; [@R50]; [@R47]; [@R32]). Nicotine (Sigma Aldrich, St. Louis, MO, N3876, 200μg/ml) was diluted in drinking water per published methodology throughout pregnancy until birth (*n*=36 pups) ([@R24]; [@R2]; [@R19]; [@R60]; [@R15]; [@R39]). Citalopram (500μg/day) was also diluted in drinking water from E13-E20 (*n*=25 pups) ([@R32]; [@R63]; [@R57]; [@R36]; [@R49]). All treatments were removed at birth of pups. Dosage was identified as midrange for preclinical studies in murine models, were replaced as needed to provide *ad libitum* access, and are based upon an average consumption of 4 ml per day for a pregnant dam. Resulting pups were grown to postnatal day 15 when they were sacrificed, and skulls were fixed with 4% paraformaldehyde, then switched to 70% Ethanol for micro-computed tomography (μCT) and finally processed for paraffin-based histology. Animal use protocols were approved by the Medical University of South Carolina Institutional Animal Care and Use Committee (AR\#3510). All breeding procedures were carried out in an Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility where all husbandry and related services are provided by the Division of Laboratory Animal Resources. Dams were exposed to only one of the pharmacological agents. All procedures and the reporting thereof are in compliance with the Animal Research: Reporting *in Vivo* Experiments (ARRIVE) guidelines ([@R38]).

2.2.. Micro-computed tomography {#S4}
-------------------------------

μCT images were obtained on postnatal day 15 mouse skulls with a SkyScan 1174 (Kontich, Belgium) at a 22.57 μm voxel resolution. Scans were obtained on 129 animals. Mouse skulls were reconstructed with NRecon v1.6.4.8 (BrukermicroCT, Kontich, Belgium) as previously described ([@R55]; [@R33]). Threshold settings were then set to only visualize bone volume within the skull. The width of the coronal and posterior interfrontal sutures were measured per published methodology at 25, 50, and 75% of its length as previously described ([@R33]). Width was defined as the distance between bony fronts.

2.3.. Immunohistochemistry {#S5}
--------------------------

For immunohistochemistry, representative samples (*n*=3) from each group (Control, levothyroxine, nicotine, citalopram) were decalcified in 0.25 M EDTA at pH 7.4 for 10 days. Skulls were then dehydrated in a graded series of ethyl alcohol (70--100%), cleared in xylene, and embedded in paraffin. Prior to embedding, the calvaria was removed from the cranial base and bisected into anterior and posterior portions anterior to the coronal suture. The anterior section was embedded to facilitate sagittal sectioning of the posterior interfrontal suture. The posterior portion was bisected along the sagittal suture to facilitate cutting through the coronal suture. Samples were sectioned on a rotary microtome and 6 μm sections were mounted on Superfrost Plus slides (ThermoFisher Scientific, Waltham, MA). Slides were subjected to an endogenous peroxidase activity block with 3% hydrogen peroxide and then washed sections were blocked in 1% goat serum or 1% donkey serum with 1% bovine serum albumin. Sections were incubated with the following primary antibodies at 4 °C overnight: Gli1 (Novus Biologicals, Centennial CO, USA, NBP1--78259, 1:500), CD44 (AbCam, Cambridge, MA, USA, ab157107, 1:100), Twist (ab50581, 1:500), Vimentin (ab11256, 1:250), Alkaline Phosphatase (ALP) (ab108337, 1:250), Active Caspase 3 (Caspase) (Ab2302, 1:75), Proliferating Cell Nuclear Antigen (PCNA) (ab18197, 1:3000). Sections were washed and incubated with HRP conjugated secondary antibody for one hour (ab6721, ab6885). Diaminobenzidine (DAB) (Vector Laboratories, Bulingame, CA) chromagen was used to identify immunoreactive structures. Suture area was digitally isolated for direct comparison between control and exposed individuals. At least 3 sections 30 μm apart per individual per treatment for each target were analyzed using Image J Software and the IHC Profiler Open Source Plugin for automated scoring of percent positivity as a means of normalizing to differing suture areas between control and exposed ([@R24]; [@R33]; [@R66]; [@R23]).

2.4.. In Vitro cell treatment {#S6}
-----------------------------

Primary, wild type suture cells were isolated as previously described ([@R24]; [@R21]), plated at a density of 65,000 cells per well in 6 well plates and treated for 7 days with control media (DMEM, supplemented with 10% FBS, 1% penstrep, and 0.2% amphotericin) or media supplemented with pharmacological agents (levothyroxine (780 ng/ml), nicotine (25 ng/ml), or citalopram (250 ng/ml)) at levels mimicking circulating levels for 7 days ([@R24]; [@R20]). Subsequently, total RNA was isolated using the Qiagen RNEasy mini kit (Qiagen, Valenica, CA, USA) according to manufacturer's protocol. Quantity and quality of RNA was assessed using a Synergy H1 Microplate reader and a Take3 Microvolume Plate (BioTek, Winooski, VT, USA). Complimentary DNA Synthesis was performed using Superscript II Reverse Transcriptase and random hexamer primer following manufacturers protocol (ThermoFisher Scientific). cDNA was subjected to quantitative PCR using Applied Biosystems TaqMan Gene Expression Master Mix and targeted TaqMan gene expression assays for stem cell related targets: *CD44* (Mm01277161_m1), *Ly6a* (Mm00726568_s1), *Gli1* (Mm00494654_m1), *Nanog* (Mm02019550_s1), *Twist* (Mm00442036_m1), *Notch1* (Mm00627185_m1), *Notch2* (Mm00803077_m1), *Notch3* (Mm01345646_m1), *Fut4* (Mm00487448_s1), *Fzd9* (Mm01206511_s1), *Stgal* (Mm00486123_m1) ([@R44]). Data were normalized to *18S* (Mm03928990_g1) ribosomal RNA expression by ΔCT. Quantitative data were compared to control (*n*=16) for gene expression change due to treatment (levothyroxine *n*=14, nicotine *n*=13, citalopram *n*=10) by AACT methodology. We used statistical analyses for qrt-PCR data as previously published to determine statistical differences for gene expression after pharmacological exposures for targets of interest ([@R69]). Differences were considered significant if *p*≤.05.

For flow cytometry, cell populations were split at passage 2 or 3 and treated for 7 days with control media, or media supplemented as above with pharmacological agents (levothyroxine *n*=13 coronal, *n*=8 posterior interfrontal, nicotine *n*=15 coronal, *n*=8 posterior interfrontal, citalopram *n*=11 coronal, *n*=8 posterior interfrontal). Cells were stained with the following antibodies: Sca1 (Ly6A, eBioscience, Waltham, MA, USA 25--5981-81, 1:2000), CD44 (BD Pharmingen, San Jose, CA, USA, 561859, 1:1000), CD45 (eBioscence, 61--0451-80,1:4000), CD34 (eBiosceince, 48--0341-80, 1:500). Zombie Violet Viability Dye (Biolegend, San Diego, CA, USA, 423114, 1:500) was used for counter staining. Cells were analyzed using the BD LSRFORTESSA flow cytometer (BD Biosciences, San Jose, CA, USA,). FlowJo v10 software was used to quantify the cell population of interest (CD44^+^, Sca1^+^, CD45^−^, CD34^−^) by both absolute number of cells, percentage of population, and median fluorescent intensity comparing to unstained control cell populations. All resources have been identified within the [key resources table](#T2){ref-type="table"}.

2.5.. Statistics {#S7}
----------------

Previous pharmacological studies in our laboratory suggested an *n*=18 per group to achieve sufficient power for our *ex vivo* measures (α=0.05, β=0.80, *r* \> 0.40) ([@R17]). Measures were screened for normality and homogeneity of variance and subjected to Student's *t*-test to compare effects by exposure; *p*≤.05 was considered significant. All statistical analyses were completed using SPSS 23.0 (IBM, Armonk, NY, USA). Data are represented as mean ± standard error of the mean.

3.. Results {#S8}
===========

3.1.. Pharmacological exposures alter craniofacial development {#S9}
--------------------------------------------------------------

Representative μCT reconstructions of post-natal day 15 skulls from mouse pups exposed *in utero* to levothyroxine (\~1 μg/day), nicotine (\~800 μg/day), and citalopram (\~500 μg/day) demonstrate dysmorphology as compared to control ([Fig. 1A](#F1){ref-type="fig"}). While there was no increase in suture fusion risk associated with the levothyroxine exposure, posterior interfrontal suture width was reduced ([Table 1](#T1){ref-type="table"}, [Fig. 1B](#F1){ref-type="fig"}). Nicotine exposure significantly increased the risk of premature posterior interfrontal suture fusion (Odds Ratio (OR)=3.08) (*p*=.014), however no significant change in either suture width was observed. As indicated by the dramatic dysmorphology of the citalopram exposed individual ([Fig. 1A](#F1){ref-type="fig"}), suture fusion risk was significantly increased for both the coronal (OR=72) and posterior interfrontal sutures (OR=6.11) (*p* \< .001). This increased fusion risk was correlated with significant narrowing of both sutures (*p* \< .001).

3.2.. Pharmacological exposures can decrease stem cells presence within calvarial sutures {#S10}
-----------------------------------------------------------------------------------------

Staining for markers associated with stem cells including Gli1, CD44, Twist and Vimentin allowed for a suture specific assessment of stem cells. Staining indicated a reduction in vimentin within the suture mesenchyme of both the coronal (*p*=.037) and posterior interfrontal sutures (*p* \< .001) exposed to levothyroxine compared to control ([Fig. 2A](#F2){ref-type="fig"}--[B](#F2){ref-type="fig"},[E](#F2){ref-type="fig"}). Conversely, nicotine exposure increased presence of CD44 (coronal *p* \< .001, posterior interfrontal *p* \< .001) and vimentin (coronal *p*=.043, posterior interfrontal *p*=.024) positivity within both sutures as compared to control ([Fig. 2 A](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}, [F](#F2){ref-type="fig"}). Quantification of stem cell marker staining in sutures from individuals exposed *in útero* to citalopram indicated a significant decrease in stem markers in both sutures. Specifically, Gli1 (*P* \< .001) and vimentin (*p*=.032) were reduced in the coronal suture, and CD44 (*p* \< .001) was reduced in the posterior interfrontal suture ([Fig. 2 A](#F2){ref-type="fig"}, [D](#F2){ref-type="fig"}, [G](#F2){ref-type="fig"}).

3.3.. Pharmacological exposures can alter cell activity within calvarial sutures {#S11}
--------------------------------------------------------------------------------

Staining for markers associated with cell activity including osteogenic differentiation *via* ALP, apoptosis (Caspase), and proliferation (PCNA) allowed for an assessment of activity within the sutures. Staining indicated a reduction in both apoptosis within the coronal suture (*p*=.003) and proliferation within both the coronal (*p* \< .001) and posterior interfrontal (*p* \< .001) sutures with *in utero* exposure to levothyroxine ([Fig. 3A](#F3){ref-type="fig"}--[B](#F3){ref-type="fig"},[E](#F3){ref-type="fig"}). Osteogenic differentiation as indicated by ALP staining was not affected by levothyroxine exposure. Interestingly, exposure *in utero* to nicotine did result in a dramatic increase in ALP staining for both the coronal (*p* \< .001) and posterior interfrontal (*p* \< .001) sutures. Apoptotic (*p* \< .001) and proliferative (*p* \< .001) activity decreased in the coronal sutures of individuals exposed *in utero* to nicotine as compared to unexposed controls ([Fig. 3 A](#F3){ref-type="fig"}, [C](#F3){ref-type="fig"}, [F](#F3){ref-type="fig"}). For the citalopram exposure, cell differentiation, apoptosis, and proliferation were not changed in the posterior interfrontal suture with exposure, however both apoptotic (*p* \< .001) and proliferative (*p*=.008) activities were reduced in the coronal suture with citalopram exposure ([Fig. 4 A](#F4){ref-type="fig"}, D, G).

3.4.. Pharmacological treatment can decrease expression of stem cell related mRNA {#S12}
---------------------------------------------------------------------------------

Cells isolated from the calvarial sutures demonstrate down-regulation of stem cell related mRNA expression with *in vitro* treatment with nicotine (25ng/ml), and citalopram (250ng/ml). Expression of stem cell related genes including the calvarial stem cell specific marker *Gli1* were unchanged with levothyroxine (780ng/ml) treatment ([Fig. 4A](#F4){ref-type="fig"}). *CD44* and *Nanog* gene expression were significantly reduced with nicotine treatment (*p*=.0055, *p*=.037 respectively) ([Fig. 4B](#F4){ref-type="fig"}). Similarly, treatment with citalopram reduced *CD44* and *Twist1* gene expression significantly (*p*=.012, *p*=.0207 respectively) ([Fig. 4C](#F4){ref-type="fig"}).

3.5.. Pharmacological treatment can decrease CD44^+^, Sca1^+^, CD34^−^, CD45^−^ stem cells {#S13}
------------------------------------------------------------------------------------------

Heterogeneous cells isolated from the coronal and posterior interfrontal sutures exposed *in vitro* to teratogens demonstrate a reduction of cells with the stem phenotype CD44^+^, Sca1^+^, CD34^−^, CD45^−^. Levothyroxine treatment did not significantly alter the cell population of interest as compared to control untreated cells ([Fig. 5 A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}). Nicotine treatment reduced the stem cell population in isolates from the coronal suture (*p*=.006) ([Fig. 5 D](#F5){ref-type="fig"}--[F](#F5){ref-type="fig"}). Citalopram treatment reduced the stem population of interest in isolates from the posterior interfrontal suture (*p*=.04) ([Fig. 5 G](#F5){ref-type="fig"}--[I](#F5){ref-type="fig"}). Overall, there was a trend towards reduction of median fluorescent intensity with each exposure particularly for the Sca1 positive population of cells ([Fig. 5 C](#F5){ref-type="fig"}, [F](#F5){ref-type="fig"}, [I](#F5){ref-type="fig"}).

4.. Discussion {#S14}
==============

Our assessment of this model of environmental exposure to pharmacological agents used to treat maternal thyroid disorder (levothyroxine), mimic maternal nicotine use, and maternal use of antidepressant SSRIs (citalopram) indicates that exposure to these agents can dramatically alter craniofacial development and stem cells. Similarities between human and murine craniofacial development make the wild-type model used here appropriate for this investigation. Without the complicating genetic predisposition to premature suture fusion, we are able to more specifically interrogate the effects of these pharmacological agents on suture maintenance ([@R21]). As it is possible that thyroid disorder and depression could spontaneously occur during pregnancy while nicotine use is more likely to occur before, after, and throughout gestation we have modeled clinically relevant conditions though our dosing schematics were different depending on the teratogen of interest. Further, a more specific assessment of the suture histologically may have revealed that rather than being fused, the suture was merely narrowed and thus not restricting craniofacial growth. This is a limitation of the thresholding and pixel size used for this μCT assessment that may reflect a need for higher resolution scanning in humans as histological investigation is inappropriate in this population. With higher resolution scanning, surgical teams can be more confident that suture growth restriction is occurring before neurosurgical intervention ([@R33]). Since the coronal suture normally remains patent in mice, the dramatic fusion rate identified with the citalopram exposure highlights a potential danger of using this medication during the period of pregnancy most closely associated with craniofacial development.

Narrowing the histological assessment of these two calvarial sutures to the suture mesenchyme specifically allowed for a characterization of cells within the fibrous space between osteogenic fronts, the capsular layer. Additionally, investigating the posterior interfrontal suture, which undergoes natural fusion around the second week of murine life provided a contrast to the normally patent coronal suture, and is the major reason for assessing these sutures at post-natal day 15 ([@R6]; [@R30]). Further, these sutures are derived from different embryological origins; posterior interfrontal is neural crest derived while the coronal suture is head mesoderm derived ([@R52]). Thus, differences between these sutures may be driven by embryological origin, natural reduction in stem cell presence due to fusion, or a multitude of other factors. Our analysis confirmed the presence of cells with a stem phenotype within the suture mesenchyme of both the coronal and posterior interfrontal sutures in correlation with the initial characterization of the calvarial sutures as a niche for stem cells ([@R71]). Quantification of percent of positive staining within the suture mesenchyme allowed normalization of the data across multiple sizes of suture as indicated by the μCT assessment.

Vimentin, a marker associated with epithelial to mesenchymal transition and neural derived stem cells is reduced with levothyroxine exposure ([@R70]). This reduction may signal early transition of cells from a stem phenotype and may perhaps indicate early quiescence of cells within the fibrous sutures ([@R33]; [@R23]). Vimentin and CD44 were enriched in the nicotine exposed sutures which may reflect the noted stimulatory effect of nicotine ([@R4]; [@R28]). Interestingly, only the citalopram exposure, which is associated with the most dramatic craniofacial abnormalities in this study, resulted in a reduction of Gli1, a defining characteristic of stem cells resident to the calvarial suture niche ([@R71]). Additionally, vimentin and CD44 were reduced with the citalopram exposure indicating that cells within the suture mesenchyme may be a heterogeneous population presenting a spectrum of stem related phenotypes. Niches are defined by their ability to maintain a stem cell population within a local tissue. Signaling between cells within and without of a particular niche is vital to the maintenance of the microenvironment ([@R49]). Perhaps by affecting multiple stem related markers, citalopram exposure precipitated the most dramatic abnormalities.

Homeostasis of cells within the suture mesenchyme is vital to maintenance of the fibrous suture space between osteogenic fronts. Since nicotine is a known stimulant ([@R62]; [@R65]; [@R11]), levothyroxine is known to preferentially affect cartilage cells ([@R33]; [@R23]; [@R21]), citalopram is known to affect bone cells ([@R34]), understanding the cell activity with regard to osteogenic differentiation, programmed cell death, and proliferation is important to understanding how these pharmacological agents affect cells within the calvarial sutures. Immunohistochemical assessment of cell activity within the suture mesenchyme after levothyroxine exposure indicated a decrease in proliferation across both sutures, and a reduction in apoptotic activity compared to control in the coronal suture. Several hypotheses for the pathogenesis of craniosynostosis focus on imbalances between the processes of cell proliferation and apoptosis of the cells that comprise the suture mesenchyme ([@R37]; [@R1]; [@R27]; [@R54]; [@R53]; [@R56]; [@R59]; [@R68]). In a normal developing skull, a balance exists between cell proliferation and apoptosis; whereas, in the craniosynostotic skull, cell proliferation is believed to be a dominant and disruptive force.

Nicotine exposure also reduced apoptotic and proliferative activity in the coronal suture, but increased osteogenic differentiation as measured by alkaline phosphatase activity in both sutures. This increase in osteogenic differentiation is consistent with an increase in bone in these areas as suggested by the increased risk of posterior interfrontal suture fusion observed with this exposure. Citalopram exposure had an expected effect of reducing both proliferation and apoptosis in the coronal suture ([@R20]), but not in the posterior interfrontal suture. The tight coordination of cellular proliferation and differentiation are known to be important for maintenance of the patent cranial sutures and eventual or pathological fusion. It is also important to note that calvarial sutures are 3-dimensional structures. As fusion may occur along the length and depth of a suture, a disruption of homeostasis within just a small part of this vital growth site may result in premature fusion and eventual disruption of normal growth and development. Overall, each of these pharmacological agents affect both craniofacial form, and structure and function of the calvarial sutures.

To assess whether these pharmacological exposures targeted stem related gene expression in addition to antigen (protein) presence, we assessed expression of a variety of classically stem associated genes in heterogeneous cells isolated from murine calvarial sutures ([@R44]). As no differences in expression profile were noted between populations of cells isolated from differing sutures, the data were collapsed to better assess gene expression in this heterogeneous population. Again, the levothyroxine exposure indicated no change as compared to control further validating that the effects of levothyroxine on murine calvarial growth may be time and region specific as well as being less dramatic than the other exposures investigated here ([@R33]; [@R23]). Though the nicotine exposure drove an increase in presence of CD44 within the calvarial sutures, expression of CD44 and other genes associated with stem phenotypes were reduced. This may indicate that nicotine drives proliferation of all phenotypes within the suture leading to altered signaling for stem cell maintenance, perhaps due to hyperplasia. The proliferative effects of nicotine may also act on the diverse cell types within the suture mesenchyme to varying degrees causing altered cell to cell signaling. Citalopram exposure reduced expression of CD44, a classical mesenchymal stem cell marker, and Twist. Reduction of Twist, as in the *Twist*^*+/*−^ murine model of craniosynostosis, is associated with dramatic craniofacial abnormalities including suture fusion, and has already been correlated with a reduction in suture specific stem cells ([@R71]).

To date, suture stem cells have been characterized by the presence of a single marker (Gli1, Axin2, Prx1) rather than by a more definitive phenotype encompassing multiple factors ([@R71]; [@R46]; [@R67]). Though overlap between Gli1, Axin2 and Prx1 populations of cells resident to the suture mesenchyme has been identified, the specific phenotype of stem cells in the suture niche remains unclear. We sought to more specifically define stem cells within the calvarial sutures, and to determine if this specifically defined population was sensitive to pharmacological exposure. Based upon the initial characterization of this population, we chose Sca1 (*Ly6a*) and CD44 as our positive markers of stem cells and CD45 and CD31 as exclusionary markers to exclude hematopoietic and immune cells from the population of calvarial derived stem cells that have been identified as mesenchymal ([@R71]).

Again, data from the levothyroxine exposure indicated no change from control correlating with the assessment that the effects of exogenous thyroid hormone exposure are time and dose specific, and can be at least partially alleviated by compensatory growth ([@R33]; [@R23]). Interestingly, the effects of the nicotine exposure on the specific CD44^+^, Sca1^+^, CD34^−^, CD45^−^ stem phenotype cells were most dramatic in the coronal suture derived populations. This may be due to the patency of this suture as compared to the fusing posterior interfrontal suture that may contain relatively fewer cells with a stem phenotype. The shift in the intensity of staining, particularly for Sca1, indicates a reduction in the presence of that specific stem cell marker further indicating a change in the phenotype of the heterogeneous cell population resident to the sutures. Citalopram exposure reduced the stem population of cells from the posterior interfrontal suture in correlation with the dramatic phenotype noted with this exposure. The variability observed in this assessment is the result of inter-individual variability. Importantly, each pharmacologically treated population of cells was compared to a matching untreated population of cells isolated from the same individual. Taken together, these data indicate that the population of cells resident to calvarial sutures is heterogeneous and the balance of cell types within this undifferentiated space may be specific to each individual precipitating the spectrum of suture fusion observed ([@R22]). Environmental exposures can affect cells within the calvarial sutures in a cell type specific manner, including by depleting resident suture stem cells.

5.. Conclusions {#S15}
===============

Together, these data indicate that environmental exposures, such as these pharmacological interventions can precipitate abnormal craniofacial growth. This corroborates the CDC data which indicates that maternal thyroid disorder, nicotine use, and SSRI use are correlated with increased risk for craniofacial abnormalities including premature calvarial suture fusion (craniosynostosis) ([@R7]; [@R12]; [@R29]). An apparent limitation to this investigation is the singular incidence of fusion in the normally patent murine coronal suture in the control group. As in humans, murine sutures exist across a spectrum between patency and fusion allowing for proper growth and development ([@R30]; [@R43]). Some of this data resulting from different experimental modalities seems to be contradictory. For example, the down-regulation of vimentin in both sutures from individuals exposed to levothyroxine is not corroborated by the suture phenotype of those individuals. This disparity potentially highlights differences in cell type and signaling between these two sutures. Additionally, the loss of Gli1 stem cells in the coronal sutures in the citalopram exposure model validates the premature fusion phenotype identified but does not extend to the other suture investigated. The increased incidence of fusion in both sutures of individuals exposed to citalopram without corroboratory protein or gene expression changes may be indicative of multiple mechanisms for suture fusion.

Our characterization of the suture stem cell population further verifies calvarial sutures as a stem cell niche and defines the resident stem population using a multi-factorial phenotype CD44^+^, Sca1^+^, CD34^−^, CD45^−^ ([@R71]; [@R46]; [@R67]). As there were differential effects of these pharmacological agents, it seems unlikely that suture stem cell depletion can be identified as a unifying mechanism of craniosynostosis, however, these data do indicate that maintenance of a balance of the heterogeneous cell phenotypes within the calvarial sutures is necessary for proper craniofacial growth and development. Further, homeostasis of cell functions including differentiation, apoptosis and proliferation is vital for proper maintenance of the calvarial sutures. Most importantly, though these medications may be required during pregnancy to manage thyroid disorders and depression, there is evidence that these exposures may negatively affect fetal development signaling a need for additional investigation.
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![Pharmacological exposures alter craniofacial development.\
A) Representative μCT reconstructions of skulls, control (no exposure), levothyroxine (1 μg/day), nicotine (800 μg/day), and citalopram (500 μg/day) demonstrate gross dysmorphology with *in utero* pharmacological exposure. Vertical arrows indicate aberrant coronal sutures and horizontal arrows indicate posterior interfrontal sutures. B) Suture width measured on 2D slices of μCT scans at 25, 50 and 75% of each suture length indicates narrowing of the posterior interfrontal suture for levothyroxine exposed, and for both sutures in individuals exposed to citalopram. \*\*=*p* \< .01, \*\*\*=*p* \< .001.](nihms-1544434-f0001){#F1}

![Pharmacological exposures can decrease stem cell presence within calvarial sutures.\
Representative coronal (left) and posterior interfrontal (right) sutures from control (no exposure) (A), levothyroxine (1 μg/day) (B), nicotine (800 μg/day) (C), and citalopram (500 μg/day) (D) in utero exposed post-natal day 15 mouse pups. Sutures have been outlined in the Gli1 stained (top row) and CD44 (second row), Twist (third row), and Vimentin (bottom row) are all displayed with periosteum above, dura, and brain below with osteogenic fronts (OF) on either side. Quantification of positive staining for levothyroxine (E), nicotine (F), and citalopram (G) exposed as compared to control indicates variation of stem cell marker presence with exposure. *n*=3 specimen × 3 sections / exposure / target \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001.](nihms-1544434-f0002){#F2}

![Pharmacological exposures can alter cell activity within calvarial sutures.\
Representative coronal (left) and posterior interfrontal (right) sutures from control (no exposure) (A), levothyroxine (1 μg/day) (B), nicotine (800 μg/day) (C), and citalopram (500 μg/day) (D) in *utero* exposed post-natal day 15 mouse pups. Sutures have been outlined in the alkaline phosphatase (ALP) stained (top row) and active caspase-3 (caspase, second row), and proliferating cell nuclear antigen (PCNA, bottom row) are all displayed with periosteum above, dura, and brain below with osteogenic fronts (OF) on either side. Quantification of positive staining for levothyroxine (E), nicotine (F), and citalopram (G) exposed as compared to control indicates variation of cell activity markers with exposure. *n*=3 specimen × 3 sections / exposure / target \*\**p* \< .01, \*\*\**p* \< .001.](nihms-1544434-f0003){#F3}

![Pharmacological Treatment can Decrease Expression of Stem Cell Related mRNA.\
Heterogeneous cells isolated from calvarial sutures treated *in vitro* with levothyroxine (780ng/ml) (A), Nicotine (25ng/ml) (B), and citalopram (250ng/ml) demonstrate differential stem cell related gene expression when compared to cells treated with control media. Note the down-regulation of *CD44* and *Nanog* mRNA with nicotine treatment and *CD44* and *Twist* mRNA with citalopram treatment as compared to control. Control *n*=16, levothyroxine *n*=14, nicotine *n*=13, citalopram *n*=10. \*p \< .05, \*\**p* \< .01.](nihms-1544434-f0004){#F4}

![Pharmacological Treatment can decrease CD44^+^, Sca1^+^, CD34^−^, CD45^−^stem cells.\
Representative plots of the stem cell population of interest (CD44 horizontal axis, Sca1 Vertical axis) from coronal (left) and posterior interfrontal (right) suture derived cells (Black=Control) overlaid with cells treated in vitro with levothyroxine (780 ng/ml) (A), nicotine (25 ng/ml) (D), and citalopram (250 ng/ml) (G) with unstained control (inset) for comparison (A, D, G). Stem cell populations remain unchanged after 7 days of in vitro treatment with levothyroxine (B). Coronal suture derived stem cells are reduced with nicotine treatment (E) and posterior interfrontal derived stem cells are reduced with citalopram treatment (H). Median fluorescent intensity for Sca1 trends down with exposure as indicated by the shift in the populations on the representative plots (C, F, I). Levothyroxine *n*=13 coronal, *n*=8 posterior interfrontal, nicotine *n*=15 coronal, *n*=8 posterior interfrontal, citalopram *n*=11 coronal, *n*=8 posterior interfrontal, \**p* \< .05, \*\**p* \< .01.](nihms-1544434-f0005){#F5}

###### 

Aberrant suture fusion risk with pharmacological exposure.

                  Coronal                                Posterior interfrontal                         
  --------------- --------- ---- ------ --------- ------ ------------------------ ---- ------ --------- -------
  Control         1         49   2.04                    19                       48   39.6             
  Levothyroxine   0         19   0                       6                        19   31.6   0.732     
  Nicotine        0         36   0                       24                       36   66.7   0.014     1.907
  Citalopram      15        25   60     \<0.001   5.44   20                       25   80     \<0.001   3.48

  Reagent or resource                                                            Source                 Identifier
  ------------------------------------------------------------------------------ ---------------------- -----------------
  Antibodies                                                                                            
  Rabbit Polyclonal Anti-Gli1                                                    Novus biological       NBP1--78259
  Rabbit Polyclonal Anti-CD44                                                    AbCam                  Ab157107
  Rabbit Polyclonal Anti-Twist                                                   AbCam                  Ab50581
  Goat Polyclonal Anti-Vimentin                                                  AbCam                  Ab11256
  Rabbit Recombinant Monoclonal Anti-Alkaline Phosphatase, Tissue Non-Specific   AbCam                  Ab108337
  Rabbit Polyclonal An6ti-Cleaved Caspase-3                                      AbCam                  Ab2302
  Rabbit Polyclonal Anti-Proliferating Cell Nuclear Antigen                      AbCam                  Ab18197
  Goat Anti-Rabbit IgG (HRP)                                                     AbCam                  Ab6721
  Donkey Anti-Goat IgG (HRP)                                                     AbCam                  Ab6885
  Ly6A/E (Sca1) Monoclonal Antiboidy (D7) PE-Cyanine7                            eBioscience            25--5981--81
  CD44 Monoclonal Antibody FITC                                                  BD Pharmingen          561859
  CD45 Monoclonal Antibody (30-F11) PE-eFluor 610                                eBioscience            61--0451--80
  CD34 Monoclonal Anitbody (RAM34) eFluor 450                                    eBioscience            48--0341--80
  Zombie Violet Viability Dye                                                    Biolegend              423,114
  Bacterial and virus strains                                                                           
  Biological samples                                                                                    
  Chemicals, peptides, and recombinant proteins                                                         
  Levothyroxine                                                                                         Synthroid
  Nicotine                                                                       Sigma aldrich          N3876
  Citalopram                                                                                            Celexa
  Critical commercial assays                                                                            
  TaqMan Gene Expression Assay *CD44*                                            Applied biosystems     (Mm01277161_m1)
  TaqMan Gene Expression Assay *Ly6a*                                                                   (Mm00726568_s1)
  TaqMan Gene Expression Assay *Gli1*                                                                   (Mm00494654_m1)
  TaqMan Gene Expression Assay *Nanog*                                                                  (Mm02019550_s1)
  TaqMan Gene Expression Assay *Twist*                                                                  (Mm00442036_m1)
  TaqMan Gene Expression Assay *Notch1*                                                                 (Mm00627185_m1)
  TaqMan Gene Expression Assay *Notch2*                                                                 (Mm00803077_m1)
  TaqMan Gene Expression Assay *Notch3*                                                                 (Mm01345646_m1)
  TaqMan Gene Expression Assay *Fzd9*                                                                   (Mm01206511_s1)
  TaqMan Gene Expression Assay *Stgal*                                                                  (Mm00486123_m1)
  TaqMan Gene Expression Assay *18 s*                                                                   (Mm03928990_g1)
  Deposited data                                                                                        
  Experimental models: cell lines                                                                       
  Experimental models: organisms/strains                                                                
  Mouse: C57BL6                                                                  Jackson laboratories   Stock \# 000664
  Oligonucleotides                                                                                      
  Recombinant DNA                                                                                       
  Software and algorithms                                                                               
  CTAN                                                                           SkyScan                
  NRecon v1.6.4.8                                                                SkyScan                
  LSRFORTESSA Fow cytometer                                                      BD                     
  FlowJo v10                                                                     FlowJo                 
  SPSS 23.0                                                                      IBM                    
  Other                                                                                                 
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